Karyopharm Therapeutics (NASDAQ:KPTI) reported Q4 2017 earnings this Morning, coming in at ($0.80) per share, missing Wall Street’s estimates of ($0.66) per Share. Revenue for the quarter came in at $1.53 million missing the streets estimates of $2.26 million Recent Insider Trading for Karyopharm Therapeutics (NASDAQ:KPTI)
- On 3/12/2018 Mansoor Raza Mirza, Director, sold 2,500 with an average share price of $17.01 per share and the total transaction amounting to $42,525.00.
- On 3/7/2018 Sharon Shacham, Insider, sold 10,000 with an average share price of $16.15 per share and the total transaction amounting to $161,500.00.
- On 3/5/2018 Christopher Brett Primiano, EVP, sold 2,500 with an average share price of $16.03 per share and the total transaction amounting to $40,075.00.
- On 2/20/2018 Michael Kauffman, CEO, sold 10,000 with an average share price of $14.79 per share and the total transaction amounting to $147,900.00.
- On 2/16/2018 Christopher Brett Primiano, EVP, sold 2,500 with an average share price of $15.01 per share and the total transaction amounting to $37,525.00.
- On 2/7/2018 Christopher Brett Primiano, EVP, sold 1,500 with an average share price of $13.00 per share and the total transaction amounting to $19,500.00.
Recent Trading for Karyopharm Therapeutics (NASDAQ:KPTI) Shares of Karyopharm Therapeutics closed the previous trading session at with shares trading hands.